Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell)

BIOLOGICAL3 trials

Sponsors

MAXVAX Biotechnology Limited Liability Company, Beijing BeneWill Technology Development Co., Ltd

Conditions

Assessing the Effectiveness of Vaccines in Preventing Adult RSV-caused Lower Respiratory Tract Disease (LRTD)Respiratory Syncytial Virus (RSV)

Phase 3

Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell)

RecruitingNCT07272434

MAXVAX Biotechnology Limited Liability CompanyRespiratory Syncytial Virus (RSV)

Start: 2025-10-22End: 2028-12-31Target: 25000Updated: 2025-12-09

Phase III Clinical Trial of Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)

RecruitingNCT07860216

Beijing BeneWill Technology Development Co., LtdAssessing the Effectiveness of Vaccines in Preventing Adult RSV-caused Lower Respiratory Tract Disease (LRTD)

Start: 2026-08-21End: 2028-12-31Target: 25000Updated: 2026-10-06

Unknown Phase

A Study to Evaluate the Immune Response Features Following Vaccination With a Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)

Not yet recruitingNCT07618325

MAXVAX Biotechnology Limited Liability CompanyRespiratory Syncytial Virus (RSV)

Start: 2026-06-02End: 2028-08-31Target: 60Updated: 2026-06-01